Member Info for BIGBONE

Volume increasing again after RNS.

Fantastic RNS this week please Vlad .

One can hope !

BWA.

Is the seller out could be interesting this afternoon.

See DS is upto 7% ,also someone is mopping up shares in the background .

Hemogenyx are going to need a monster RNS to recover the share price after it was run up again typical bio company scenario, luckily we still have a few RNS's to come but will the top boys let it run ?

Nice one Vald. Great for pointing out the science and which way is up to the wider herd to follow.

ATB

Hemogenyx is a lot further on now and still valued at 2p pre consolidate. Something big going on behind the science holding this back , will it just pop one day ?

Dotting the i's and thevT's it is then . Monday morning RNS after Transcripts put to paper.

Thanks for the reply though.

HGD.

Digital

I guess we will find out in the morning if it is or isn't.

P.s all are welcome in Hereford its a lovely place to live and have a beer !

Ai but factual.

As of 5:20 PM GMT, March 19, 2026, Dr. Vladislav Sandler has concluded his strategic update at the LSI USA ’26 Emerging Medtech Summit in California.

​While a formal Regulatory News Service (RNS) transcript is often released the following morning in the UK, the following factual and positive points were confirmed during the presentation and corroborated by recent broker activity:

​1. Positive Clinical Facts

​Safety De-risking: Dr. Sandler confirmed that the Phase I trial for HG-CT-1 (CAR-T for AML) has successfully passed its initial safety assessments with no dose-limiting toxicities (DLTs) in the first cohort.

​Dose Escalation: The trial is officially moving into higher dose cohorts for adult patients. This is a critical milestone, as higher doses are where efficacy (cancer-killing potential) typically becomes more visible.

​Pediatric Opening: Recruitment is now active for patients aged 12–18. This is factually positive as it broadens the market and addresses a significant unmet medical need.

​"One-Day" Manufacturing: The transition to Made Scientific (New Jersey) is in its final stages. The goal is to reduce the CAR-T manufacturing cycle to just 24 hours, which would be a massive competitive advantage in the cell therapy space.

​2. Broker & Market Intelligence

​SP Angel (Corporate Broker): Their recent notes maintain a focus on the "de-risking" nature of the current Phase I progress. They highlight the £2.5 million raised in February 2026 as sufficient to fund these clinical milestones through the near term.

​Market Ratings: Consensus remains a "Hold/Buy" among specialized biotech analysts (e.g., MarketBeat aggregators), with the recent 400-to-1 share consolidation having stabilized the price action around the £11.00 range (post-consolidation pricing).

​Revenue Outlook: Brokers are increasingly noting the Estonian "Hospital Exemption" pathway. Factually, this allows Hemogenyx to potentially generate revenue via government reimbursement in the EU before full Phase II/III completion—a rare "early-revenue" feature for a biotech at this stage.

​3. Investor Sentiment

​Sentiment from the summit floor is described as "optimistic," specifically regarding the CBR (Chimeric Bait Receptor) platform's secondary application in biodefense, which has begun attracting interest beyond traditional oncology investors

While we are still waiting for a formal RNS (Regulatory News Service) update or a full transcript of the talk, here is the pulse from the event:

​The Vibe: Investor sentiment on the ground and in active trading circles was optimistic. The focus of the talk was on the HG-CT-1 Phase I trials and the company’s broader pipeline, including the CBR (Chimeric Bait Receptor) platform.

​Clinical Progress: There is significant anticipation regarding the dose-escalation phase. Discussions earlier today leaned into the potential for "clean" safety data and the upcoming "technology transfer" to Made Scientific, which is seen as a major step toward commercial scalability.

Slow after noon but at least these guys at SP Angel Corporate Finance LLP have it all in order and have doted the ts and i's

​They work alongside the company's broker, Albis Capital formerly Peter house but must have plugged the holes no leaks yet.lets hope the proof reading is done and we get a lovely written RzNS tomorrow 😀

Mr Bingpot

Great to beat top of the league yesterday 2-1 .

Just hope they bring some of their youth team through some cracking players especially the goal keeper got them through the first few rounds of FA until caddy put his second keeper in who got injured instead of using the youth. Any way he has gone now and looks like Hereford are on the up. Ended up at Herefords premier night spot the wobbly lol.

Weather spoons in Hereford is called the. kings fee , Also Hereford have a home game this afternoon , Best traditional beer is in the Barrels , wye valley can recommend the IPA.. I'm sure Bingpot will know the Barrels.

Big buys rolling in GLA

Good to know that all 6 of the group are poster on here gives ballance against the fud.

Pumpky.

Before the new warrants £360 would of been roughly company value £2b , Hemogenyx now so much further down the road surly a starting value for sale £5b Hemogenyx only company treating AML with results so far looking really positive for patients and company.then there are the other pipe lines possibly even more valued. LTH

DYOR .all

Hemo ,Delta gold tech and Ark for me .

#Digit

He became an international sensation, earning the nicknames "Baghdad Bob" in the US and "Comical Ali" in the UK for his bombastic, colorful, and wildly inaccurate press briefings. His "comedy gold" status came from his absolute refusal to acknowledge reality, even when it was visible directly behind him.

Group Eleven Resources is in the final 24 hours of its massive funding round.

​Group Eleven Resources (ZNG.V)

​Financing Deadline: The company is expected to close its C$10.4 million "bought deal" private placement tomorrow, March 11, 2026. This follows an upsize from the original C$9 million due to high demand.

​Drilling Momentum: While no new assays were released today, the company recently confirmed they have four rigs currently turning at the Ballywire discovery. Investors are awaiting the next batch of results from hole 25-3552-51, where partial assays already showed over 50m of high-grade mineralization.

​Arkle Resources (ARK.L)

​Stock Activity: Arkle shares have shown a strong upward trend recently, gaining nearly 18% over the last two weeks. Technical analysts have noted a "Bullish Trend" as the company shifts its identity toward uranium exploration.

​Namibia Focus: The market is currently waiting on the first progress update from their newly commenced Phase 1 exploration program in the Erongo Belt, Namibia.